Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6130)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 24, 2022 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Medina López RA, Rivero Belenchon I, Mazuecos-Quirós J, Congregado-Ruíz CB, Couñago F. Update on the treatment of metastatic renal cell carcinoma. World J Clin Oncol 2022; 13(1): 1-8 [PMID: 35116228 DOI: 10.5306/wjco.v13.i1.1] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v13/i1/1.htm |
| Number | Citing Articles |
| 1 |
Liliana Eleonora Semenescu, Amira Kamel, Vasile Ciubotaru, Silvia Mara Baez-Rodriguez, Mircea Furtos, Alexandra Costachi, Anica Dricu, Ligia Gabriela Tătăranu. An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases. Current Issues in Molecular Biology 2023; 45(9): 7680 doi: 10.3390/cimb45090485
|
| 2 |
Kento Morozumi, Yoshihide Kawasaki, Tomonori Sato, Masamitsu Maekawa, Shinya Takasaki, Shuichi Shimada, Takanari Sakai, Shinichi Yamashita, Nariyasu Mano, Akihiro Ito. Elucidation and Regulation of Tyrosine Kinase Inhibitor Resistance in Renal Cell Carcinoma Cells from the Perspective of Glutamine Metabolism. Metabolites 2024; 14(3): 170 doi: 10.3390/metabo14030170
|
| 3 |
Weijie Yan, Naiqiao Hou, Junhua Zheng, Wei Zhai. Predictive genomic biomarkers of therapeutic effects in renal cell carcinoma. Cellular Oncology 2023; 46(6): 1559 doi: 10.1007/s13402-023-00827-4
|
| 4 |
Mona Abdellateif, Ahmed Bayoumi, Mohammed Mohammed. c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights. OncoTargets and Therapy 2023; : 785 doi: 10.2147/OTT.S404648
|
| 5 |
Bae-Hoon Kim, Yeon-Ho Chung, Tae-Gyun Woo, So-mi Kang, Soyoung Park, Minju Kim, Bum-Joon Park. NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues. International Journal of Molecular Sciences 2024; 25(12): 6558 doi: 10.3390/ijms25126558
|
| 6 |
Karina L. Bursch, Christopher J. Goetz, Guanming Jiao, Raymundo Nuñez, Michael D. Olp, Alisha Dhiman, Mallika Khurana, Michael T. Zimmermann, Raul A. Urrutia, Emily C. Dykhuizen, Brian C. Smith. Cancer-associated polybromo-1 bromodomain 4 missense variants variably impact bromodomain ligand binding and cell growth suppression. Journal of Biological Chemistry 2024; 300(4): 107146 doi: 10.1016/j.jbc.2024.107146
|
| 7 |
Weipu Mao, Keyi Wang, Wentao Zhang, Shuqiu Chen, Jinbo Xie, Zongtai Zheng, Xue Li, Ning Zhang, Yuanyuan Zhang, Haimin Zhang, Bo Peng, Xudong Yao, Jianping Che, Junhua Zheng, Ming Chen, Wei Li. Transfection with Plasmid-Encoding lncRNA-SLERCC nanoparticle-mediated delivery suppressed tumor progression in renal cell carcinoma. Journal of Experimental & Clinical Cancer Research 2022; 41(1) doi: 10.1186/s13046-022-02467-2
|
| 8 |
Liwen Ren, Yihui Yang, Wan Li, Hong Yang, Yizhi Zhang, Binbin Ge, Sen Zhang, Guanhua Du, Jinhua Wang. Recent advances in epigenetic anticancer therapeutics and future perspectives. Frontiers in Genetics 2023; 13 doi: 10.3389/fgene.2022.1085391
|
| 9 |
Martina Catalano, Luigi Francesco Iannone, Federica Cosso, Daniele Generali, Enrico Mini, Giandomenico Roviello. Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment. Expert Opinion on Therapeutic Targets 2022; 26(11): 923 doi: 10.1080/14728222.2022.2158813
|
| 10 |
Vinay Sonawane, Jeevan Ghosalkar, Swati Achrekar, Kalpana Joshi. Ketorolac modulates Rac-1/HIF-1α/DDX3/β-catenin signalling via a tumor suppressor prostate apoptosis response-4 (Par-4) in renal cell carcinoma. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-32627-z
|
| 11 |
Martina Catalano, Ugo De Giorgi, Davide Bimbatti, Sebastiano Buti, Giuseppe Procopio, Pierangela Sepe, Matteo Santoni, Luca Galli, Raffaele Conca, Laura Doni, Lorenzo Antonuzzo, Giandomenico Roviello. Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib. Clinical Genitourinary Cancer 2024; 22(2): 514 doi: 10.1016/j.clgc.2024.01.006
|